Tag: GlobeNewswire

Company Announcement

COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026

• EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients
• Based on the topline results, Genmab and AbbVie will engage global regulatory authorities

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5. The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in DLBCL patients with an IPI score of 2 to 5. The risk of disease progression or death was reduced by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001). The safety profile of epcoritamab when administered in combination with standard of care R-CHOP was generally well tolerated and consistent with the previously reported safety profiles of the individual agents (epcoritamab and R-CHOP).

“These topline results of epcoritamab in combination with R-CHOP mark the first Phase 3 study to demonstrate a statistically significant improvement in progression-free survival in patients with newly diagnosed DLBCL treated with a bispecific antibody combination and have the potential to reshape the frontline treatment landscape,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “While treatment advances have improved outcomes for patients with diffuse large B-cell lymphoma, options for newly diagnosed patients remain limited, reinforcing the need for additional therapies that can treat as many patients as possible in the frontline setting.”

“DLBCL is an aggressive disease and the need to advance treatment options is critical. These positive topline results suggest that epcoritamab combined with R-CHOP could offer a potential new standard of care in newly diagnosed DLBCL patients,” said Daejin Abidoye, MD, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. “The findings further strengthen our understanding and potential of bispecifics across the lymphoma treatment landscape, as we work to address urgent needs in this patient population.”

“As an investigator with firsthand experience in both the landmark trial that established R-CHOP as a standard of care nearly 25 years ago and EPCORE DLBCL-2, it is particularly meaningful to see the potential benefit of bispecific antibody therapy in newly diagnosed diffuse large B-cell lymphoma,” said Gilles Salles, MD, PhD, Chief of the Lymphoma Service and holder of the Steven A. Greenberg Chair at Memorial Sloan Kettering Cancer Center. “The 51% reduction in the risk of progression or death is clinically meaningful and highly relevant to everyday practice. These results have the potential to be practice-changing and could mark an important step forward in bringing the opportunity of cure to more patients.”

Data will be submitted for presentation at a future medical meeting. Genmab and AbbVie will engage global regulatory authorities to determine next steps. Epcoritamab plus R-CHOP is an investigational combination not approved by regulatory authorities.

About the EPCORE^® DLBCL-2 Trial 
EPCORE DLBCL-2 (NCT05578976) is a global Phase 3 open label, multi-center, randomized trial to evaluate the efficacy of fixed duration, subcutaneous epcoritamab (GEN3013, DuoBody^®-CD3xCD20) and standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) compared to R-CHOP alone in patients with newly diagnosed large B-cell lymphoma (DLBCL). The trial enrolled subjects with an International Prognostic Index (IPI) score of 2 to 5, including patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B), T-cell/histiocyte-rich large B-Cell lymphoma (TCHR LBLC), and Epstein-Barr Virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL). The primary endpoint is PFS in participants with an International Prognostic Index (IPI) of 3-5 and the key secondary endpoint is PFS in total participants (IPI score of 2-5). The risk of disease progression or death for the primary endpoint population was reduced by 51% (HR 0.49 [95% CI 0.35, 0.69]; p-value < 0.0001). Patients were randomized 2:1 to receive a fixed-duration regimen of epcoritamab plus R-CHOP for six cycles followed by epcoritamab alone for two cycles, or R-CHOP for six cycles followed by rituximab for two cycles. The trial started on February 8, 2023, and is ongoing.

More information on this trial can be found at https://clinicaltrials.gov/study/NCT05578976 (NCT: NCT05578976).

About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.^i,ii In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year.ⁱⁱⁱ DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.^iv,v DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.^iv,vi

About Epcoritamab 
Epcoritamab is an IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology and administered subcutaneously. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.^vii

Epcoritamab (approved under the brand name EPKINLY^® in the U.S. and Japan, and TEPKINLY^® in the EU) has received regulatory approval in certain lymphoma indications in more than 65 countries. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the relapsed or refractory (R/R) follicular lymphoma (FL) indication and additional approvals for the R/R diffuse large B-cell lymphoma (DLBCL) indication. 

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R²) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.

About Genmab  
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram. 

About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio is comprised of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 35 investigational medicines across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit us at http://www.abbvie.com/oncology.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Genmab Contacts:         Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com	AbbVie Contacts: Raquel Powers, Director, Oncology Public Affairs T: +1 847 935 6563; E: raquel.powers@abbvie.com
Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com	Todd Bosse, Vice President, Investor Relations T: +1 847-936-1182; E: todd.bosse@abbvie.com

Genmab Forward-Looking Statements
This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO™. EPCORE^®, EPKINLY^®, TEPKINLY^® and their designs are trademarks of AbbVie Biotechnology Ltd. Dr. Salles has financial interests related to AbbVie and Genmab.

AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

---

ⁱ Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed February 2026. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/ 
ⁱⁱ Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.
ⁱⁱⁱ Leukemia and Lymphoma Society. Diffuse Large B-Cell Lymphoma (DLBCL). Accessed February 2026. https://www.lls.org/research/diffuse-large-b-cell-lymphoma-dlbcl 
^iv Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. doi: 10.1056/NEJMra2027612.
^v Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188.
^vi Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study. Blood. 2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.
^vii Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625.

Company Announcement no. 40
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 05102026_CA40_EPCORE DLBCL-2 (Global)

BEDMINSTER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) —

Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) and Peapack Private Bank & Trust are pleased to announce the appointment of Ana Parra as Senior Managing Director, Group Director.  Based in the Bank’s Park Avenue office in Manhattan, she will focus on serving the complex financial needs of high-net-worth individuals, families, family offices, and privately held businesses while leading a team dedicated to delivering customized private banking solutions.

Parra brings more than 35 years of banking experience in private banking, relationship management, client service, lending coordination, deposit growth, treasury management, and wealth management referrals.  Throughout her career, she has built trusted client relationships and provided strategic guidance tailored to clients’ evolving financial needs through a highly personalized approach to banking.

Prior to joining Peapack Private, Parra served as Vice President, Relationship Manager and Private Banker at IDB Bank.  In that role, she managed relationships for high-net-worth individuals, family offices, and operating companies across deposit, credit, liquidity, treasury, and wealth management services.  She also played a key role in retaining and expanding client relationships and served as a trusted advisor to clients and their families.  Most notably, Parra assumed leadership of a portfolio of high-net-worth client relationships totaling approximately $300 million, successfully maintaining those relationships through her commitment to responsive service, trusted advice, and a client-centric approach to banking. 

Earlier in her career, Parra spent approximately a decade at Signature Bank, where she supported senior banking leadership and helped deliver customized banking solutions to relationship-focused clients.  She began her career in branch banking with Manhattan Savings Bank and subsequently advanced through positions with Republic National Bank and HSBC, gaining experience in client relationship development, account management, and banking operations.

About the Company
Peapack-Gladstone Financial Corporation is a New Jersey bank holding company with total assets of $8.0 billion and assets under management and/or administration of $13.9 billion as of June 30, 2026. Founded in 1921, Peapack Private Bank & Trust is a commercial bank that offers a client-centric approach to banking, providing high-quality products along with customized and innovative wealth management, investment banking, commercial and personal banking solutions. The Bank’s wealth management division offers comprehensive financial, tax, fiduciary and investment advice and solutions to individuals, families, privately held businesses, family offices, and not-for-profit organizations, which help them establish, maintain, and expand their legacy. Peapack Private Bank & Trust offers an unparalleled commitment to client service. Visit www.peapackprivate.com for more information.

###

Contact:  Rosanne Schwab, Peapack Private Bank & Trust, Vice President, Public Relations and Corporate Communications Manager, 500 Hills Drive, Suite 300, Bedminster, NJ  07921 rschwab@peapackprivate.com, (908) 719-6543.

Attachment

• Ana Parra

Iceland Seafood International hf. has concluded an offering of 6-month bills in the new series ICESEA 27 0407.
Total offers for bills in the auction amounted to ISK 1.080 million and offers were accepted for ISK 580 million at a simple rate of 8.82%. The bills are scheduled to be admitted to trading on Nasdaq Iceland in the coming weeks.  

Disclosure of treasury shares transactions carried out from September 28 to October 2, 2026

Attachment

• BUREAU VERITAS – Reporting agrégé du 28 septembre au 2 octobre 2026 (vENG)

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Discovery Mining Ltd. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today confirmed that the Company has received the Cordero Project’s (“Cordero” or the “Project”) environmental impact assessment (“Manifesto de Impacto Ambiental” or “MIA”) permit and the Change of Land Use permit (“Change of Land Use”) from Mexico’s Federal Environmental Department (“SEMARNAT”). Receipt of the MIA and Change of Land Use permits completes the federal environmental permitting process and positions the Company to advance Cordero towards development.

Tony Makuch, Discovery’s President, CEO and Chairman, commented: “We want to thank the Mexican regulators and authorities for their trust in us as we advance Cordero forward as a model of sustainability for all stakeholders. Cordero is a large-scale silver project that will produce the right mix of critical metals the world needs, with minimal negative environmental impact, while improving the use of water resources in the region, and generating substantial socio-economic benefits for Mexico. The project will create thousands of jobs, provide considerable training and multi-generational skills development, and will deliver significant economic contributions to the region and the country.”

ABOUT DISCOVERY

Discovery Mining Ltd. is a growing precious metals company that is creating value for stakeholders through exposure to gold, silver and other critical minerals. Discovery’s silver exposure comes mainly from the 100%-owned Cordero project, one of the world’s largest undeveloped silver deposits, which is located close to infrastructure in a prolific mining belt in Chihuahua State, Mexico. In Canada, the Company is advancing plans to more than double annual gold production through investment in its Porcupine assets, which include multiple operations, attractive growth projects and significant exploration upside in one of the world’s most renowned gold camps in and near Timmins, Ontario. The acquisition of the Kidd Operations in June 2026 further increased Discovery’s land position within the camp, provided valuable infrastructure that will support the Company’s growing gold business, and added critical minerals to the Company’s current production profile.

On Behalf of the Board of Directors,

Tony Makuch, P. Eng
President, CEO & Chairman

For further information contact:         
Mark Utting, CFA
EVP, Investor Relations and Communications
Phone: 416-806-6298
Email: mark.utting@dsvmining.com
Website: www.dsvmining.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements relating to expected future events, including without limitation the advancement of the development of the Cordero Project and the Company’s growth plans, all of which involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results and growth plans may change, and may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures); price of gold, silver and other commodities; timing of receipt of permits, availability of water and power, availability of labour and other local economics, and the other risks and uncertainties discussed in the materials filed by the Company with the Canadian securities regulatory authorities and available on SEDAR+ at www.sedarplus.ca.

Discovery disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. 

Panel Determines Company Has Regained Compliance With Nasdaq Continued Listing Requirements; Trading on Nasdaq to Be Reinstated on a Date to Be Set by Nasdaq

MIDDLETON, Mass, Oct. 05, 2026 (GLOBE NEWSWIRE) —  SCWorx Corp. (OTCQB: WORX) (the “Company”), a provider of data management solutions to healthcare providers, today announced that on October 2, 2026, the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for reconsideration of the Panel’s September 17, 2026 decision to delist the Company’s common stock from The Nasdaq Stock Market LLC (“Nasdaq”). In its October 2, 2026 decision, the Panel determined that the Company now demonstrates compliance with the continued listing requirements of Nasdaq, including the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) and the minimum publicly held shares requirement of Nasdaq Listing Rule 5550(a)(4), and granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to the conditions described below.

Trading in the Company’s common stock on Nasdaq, which has been suspended since April 14, 2026, will be reinstated on a date to be scheduled by Nasdaq. The Company is submitting Nasdaq’s reinstatement form today and expects to announce the reinstatement date once it is confirmed by Nasdaq. Until trading on Nasdaq is reinstated, the Company’s common stock will continue to be quoted on the OTCQB Venture Market under the symbol “WORX.”

The Panel’s decision followed the Company’s September 16, 2026 private placement, which, together with the exercise of outstanding warrants, increased the Company’s publicly held shares to 549,092 shares as of September 17, 2026, above the 500,000-share minimum required by Nasdaq Listing Rule 5550(a)(4). On September 30, 2026, the Nasdaq Listing Qualifications Staff confirmed that the Company had regained compliance with the publicly held shares requirement as of September 17, 2026. The Company’s closing bid price has been at or above $1.00 per share on every trading day since August 4, 2026, including the 10 consecutive trading days following September 17, 2026 required under Nasdaq Listing Rule 5810(c)(3)(A).

“We are pleased that the Panel has recognized the steps the Company has taken to regain compliance with Nasdaq’s listing requirements and look forward to the resumption of trading on Nasdaq,” said Tim Hannibal, CEO of SCWorx.

As a condition of continued listing, the Panel required the Company to publicly disclose that each investor in the September 2026 private placement has agreed that it will not exercise its contractual right under the securities purchase agreement to terminate its purchase based on the Panel’s September 17, 2026 decision. Each of the investors has delivered that agreement to the Company. The Panel also imposed a Discretionary Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(A) for a one-year period ending October 2, 2027, and required the Company to provide monthly reports of its shares outstanding, insider holdings and public float to Nasdaq through October 5, 2027. If Nasdaq determines that the Company fails any continued listing standard during the monitor period, the Company will not be permitted to submit a compliance plan or receive a cure or compliance period, and Nasdaq will promptly issue a Staff Delisting Determination, which the Company would be entitled to appeal to a Hearings Panel.

Additional information regarding the Panel’s decision and the investor agreements is set forth in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 5, 2026.

About SCWorx Corp.

SCWorx provides data management solutions to healthcare providers. The Company’s solutions are designed to improve the accuracy, standardization and utilization of healthcare supply-chain data and support healthcare organizations in managing their item master and related supply-chain information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the reinstatement of trading in the Company’s common stock on The Nasdaq Capital Market and the timing thereof, the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements and the conditions of the Panel’s decision, and the potential exercise by the private placement investors of their termination rights. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that Nasdaq delays or does not reinstate trading in the Company’s common stock, the risk that the Nasdaq Listing and Hearing Review Council calls the Panel’s decision for review and modifies or reverses it, the risk that the Company fails to satisfy a Nasdaq continued listing standard during the Panel Monitor period, in which case the Company would not be afforded a compliance plan or cure period, the risk that the private placement investors exercise their termination rights, and the other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Contact

SCWorx Investor Relations

ir@scworx.com

Hydro provides an update on the natural gas supply situation at the Alunorte alumina refinery.

Alunorte was informed in August 2026 by its supplier CELBA of disruptions to natural gas availability. Consequently, Alunorte has not received contracted gas deliveries and is currently sourcing gas in the market at spot based prices. Alunorte is in parallel progressing a long-term gas supply solution on competitive terms.

Hydro reported on the potential financial and production impact for the third quarter of 2026 in mid-August this year, estimating a lost alumina production of 100,000 to 120,000 tonnes and a financial impact of USD 75 to 100 million for Bauxite & Alumina. For the fourth quarter of 2026, the estimated cost impact of the difference between contract price and spot based gas prices for Alunorte is between USD 90-110 million.

Alunorte does not expect further interruption to gas supply as a result of the current situation and continues to manage the matter in close collaboration with infrastructure owner CELBA and the relevant authorities.

The financial impact remains uncertain and is subject to gas prices, contractual developments, and the implementation of a long-term solution.

Alunorte is also pursuing available legal remedies and other measures to protect its contractual rights and interests under the existing gas supply agreement.

Investor contact: 

Gerd Aalborg Aas

+47 913 05 534

Gerd.Aalborg.Aas@hydro.com: 

Valentina Gandolfi

+47 958 82 355

Valentina.Gandolfi@hydro.com 

Press Release

           Paris – 05 October 2026

Share Transactions Disclosure

Banijay Group N.V. (894500G73K46H93RF180) declares the following transactions made on its own shares (NL0015000X07) from 28 September to 02 October 2026 in accordance with the authorization given by the shareholder’s annual meeting on 27 May 2026.

Trade Date	Side	Total Daily Volume (Number of Shares)	Average Price	Amount of Transactions	Market Identification Code
2026-09-28	BUY	650	8.288000	5 387.20	XAMS
2026-09-28	SELL	279	8.312832	2 319.28	XAMS
2026-09-29	BUY	260	8.272308	2 150.80	XAMS
2026-09-29	SELL	393	8.283053	3 255.24	XAMS
2026-09-30	SELL	164	8.280000	1 357.92	XAMS
2026-10-01	BUY	411	8.227251	3 381.40	XAMS
2026-10-01	SELL	124	8.240000	1 021.76	XAMS
2026-10-02	SELL	100	8.220000	822.00	XAMS

The disclosure of all share transactions was made publicly available and can be consulted on the company’s website (https://group.banijay.com/liquidity-agreement/) under the section « Investors ».

Investor Relations

investors@group.banijay.com

Press Relations

banijaygroup@brunswickgroup.com  

About Banijay Group

Banijay Group is a global entertainment leader founded by Stéphane Courbit, an entrepreneur and entertainment industry pioneer with more than 30 years of experience in the industry. Its mission is to inspire passion by providing audiences with engaging and innovative entertainment experiences. The Group’s activities include Entertainment & Live gathering content production & distribution and Live experiences (through Banijay Entertainment, the world’s largest independent production company) and Sports betting & Gaming (through Banijay Gaming, Europe’s fast-growing sports betting platform, encompassing leading brands including Betclic and since April 2026, Tipico and Admiral).
In 2025, Banijay Group recorded on a standalone basis (before Tipico and All3Media operations) revenue of €4.9 billion and Adjusted EBITDA of €961 million. Banijay Group is listed on Euronext Amsterdam (ISIN: NL0015000X07, Bloomberg: BNJ NA, Reuters: BNJ.AS).

Attachment

• 2026.10.05 – Banijay Group – Weekly share transactions – PR

Company announcement No. 53 / 2026

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that the share buy-back program (the “Program”) initiated on May 7, 2026 has been completed. The lead manager, Danske Bank, exercised its option to close the Program ahead of October 31, 2026, after the planned aggregate amount of approximately DKK 1,300 million was reached. The Company also reports transactions under the Program for week 40 (September 28 – October 2, 2026) and week 41 (October 5, 2026).

The Program was carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which set out the full terms of the Program. Under the Program, Zealand Pharma was authorized to repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that could be acquired under the Program was 7,152,557. The Program commenced on May 7, 2026, and was completed on October 5 2026, ahead of the original deadline of October 31, 2026. The Company appointed Danske Bank as lead manager for the Program. Danske Bank made its own trading decisions independently of, and without influence from, the Company.

During the Program, a total of 4,408,500 shares were repurchased at an average price of DKK 294.88, corresponding to a total gross value of DKK 1,299,996,125.

Transactions executed in week 40 and week 41
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during week 40 (September 28, 2026 – October 2, 2026) and week 41 (October 5, 2026):

Date	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated as per latest announcement	3,940,000		1,176,114,320
28/09/2026	70,000	271.14	18,979,800
29/09/2026	70,000	270.57	18,939,900
30/09/2026	70,000	270.98	18,968,600
01/10/2026	85,000	248.88	21,154,800
02/10/2026	90,000	261.76	23,558,400
Accumulated (W40)	385,000		101,601,500
05/10/2026	83,500	266.83	22,280,305
Accumulated (W41)	83,500		22,280,305
Total accumulated under the Program	4,408,500	294.88	1,299,996,125

Treasury shares and share capital
Following the transactions described above, Zealand Pharma holds a total of 5,279,342 treasury shares, corresponding to approximately 7.37% of the Company’s share capital.

The total number of shares in Zealand Pharma is 71,610,005, each with a nominal value of DKK 1.

Additional information
Detailed information on each transaction executed under the Program is available in the appendix to this company announcement.

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com

Andreas Hylleberg Mølleskov (Media) 
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com

Attachments

• 20261005 – Company announcement – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
• Zealand Pharma – Share buy back – Transactions in week 40 + 41

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

FOR IMMEDIATE RELEASE

5 October 2026

RECOMMENDED CASH OFFER

FOR

IRISH CONTINENTAL GROUP, PLC

BY

BLUEFIN BIDCO LIMITED

TO BE IMPLEMENTED BY WAY OF A SCHEME OF ARRANGEMENT UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014

ANNOUNCEMENT OF DATE OF COURT HEARING TO SANCTION THE SCHEME AND SATISFACTION OF NSIA CONDITION

On 24 July 2026, the Independent Directors of Irish Continental Group, plc (the Independent ICG Board) and the board of Bluefin Bidco Limited (BidCo) announced that they had agreed the terms of a recommended acquisition (the Acquisition) of the entire issued and to be issued share capital of Irish Continental Group, plc (ICG).  The Acquisition is to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 (the Scheme), which is subject to the terms and conditions set out in the scheme document published by ICG on 5 August 2026 (the Scheme Document).

ICG Shareholders voted in favour of the Acquisition at the Scheme Meetings and Extraordinary General Meeting held on 10 September 2026.  

Announcement of Date of Court Hearing to Sanction the Scheme

The Independent ICG Board announces that the hearing of the application by ICG to the High Court of Ireland (the Court) for an order sanctioning the Scheme and related matters (the Court Hearing), has been listed by the Court for hearing at 11:00am (GMT) on 10 November 2026 (or such later date as the Court may direct).

Information on the Court Hearing (or, if relevant, a change in the date of the Court Hearing) will be advertised on the Company’s website www.icg.ie.  By Order of the Court, any interested party intending to appear at the Court Hearing must give notice of their intention to do so to the Company’s solicitors, A&L Goodbody LLP, by email addressed to Hannah Shaw at hshaw@algoodbody.com by no later than 5:30pm (GMT) on Friday, 23 October 2026. Any affidavit evidence that an interested party intends to rely on at the Court Hearing must be filed with the Central Office of the Court and served on the Company’s solicitors, A&L Goodbody LLP, by that time and date. A copy of the originating notice of motion and the supporting affidavit may be obtained from the Company’s solicitors A&L Goodbody LLP, upon request made by email addressed to Hannah Shaw at hshaw@algoodbody.com. 

Satisfaction of NSIA Condition 

The Independent ICG Board is pleased to announce that on 2 October 2026 the Secretary of State notified Bidco that no further action will be taken in relation to the Acquisition under the UK National Security and Investment Act 2021. Accordingly, Condition 3.1 (as set out in Part V of the Scheme Document) has now been satisfied.

Effective Date and Timetable

Completion of the Acquisition remains subject to the satisfaction or waiver of the other Conditions set out in the Scheme Document including the sanction by the Court of the Scheme at the Court Hearing (the Conditions).

Subject to satisfaction or waiver of the Conditions, the Effective Date of the Scheme and closing of the Acquisition is currently expected to be some time in November 2026.

Except as otherwise defined herein, capitalised terms used but not defined in this Announcement have the same meanings as given to them in the Scheme Document.

Enquiries

Irish Continental Group, plc Brian Holland	+353 1 607 5700 investor.relations@icg.ie
PJT Partners (UK) Limited (Financial Adviser and Rule 3 Adviser to ICG) Basil Geoghegan Ronan Crotty Henry Lebus	+44 (0)20 3650 1100
Q4 Public Relations (Public Relations Adviser to ICG) Gerry O’Sullivan	+353 87 259 7644 gerry@q4pr.ie

Responsibility Statement

The Independent ICG Board accept responsibility for the information contained in this Announcement, To the best of the knowledge and belief of the Independent ICG Board (which has taken all reasonable care to ensure such is the case), the information contained in this Announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. 

Adviser

PJT Partners, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively as financial adviser to ICG and no one else in connection with the matters described herein and will not be responsible to anyone other than ICG for providing the protections afforded to clients of PJT Partners nor for providing advice in connection with the matters described herein. Neither PJT Partners nor any of its subsidiaries, branches or affiliates nor any of their respective directors, officers, employees, agents or representatives owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of PJT Partners in connection with this Announcement, the Acquisition, any statement contained herein or otherwise.

No Offer or Solicitation

This Announcement is for information purposes only and is not intended to, and does not, constitute or form any part of any offer or invitation, or the solicitation of an offer, to purchase or otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The Acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer Documents), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Acquisition. Any decision in respect of, or other response to, the Acquisition, should be made only on the basis of the information contained in the Scheme Document (or, if applicable, the Takeover Offer Documents).

This Announcement does not constitute a prospectus or a prospectus equivalent document.

Cautionary Statement Regarding Forward-Looking Statements

This Announcement may contain certain forward-looking statements with respect to ICG. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts and can generally, but not always, be identified by the use of words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should” or their negative variants or other variations. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ICG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Announcement. ICG undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent legally required.

Disclosure requirements of the Takeover Rules

Under Rule 8.3(b) of the Irish Takeover Rules, any person ‘interested’ (directly or indirectly) in 1% or more of any class of ‘relevant securities’ of ICG must disclose all ‘dealings’ in such ‘relevant securities’ during the ‘offer period’. The disclosure of a ‘dealing’ in ‘relevant securities’ by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (Irish/UK time) on the business day following the date of the relevant transaction. This requirement will continue until the ‘offer period’ ends. If two or more persons cooperate on the basis of any agreement either express or tacit, either oral or written, to acquire an ‘interest’ in ‘relevant securities’ of ICG, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules. A dealing disclosure must contain the details specified in Rule 8.6(b) of the Irish Takeover Rules, including details of the dealing concerned and of the person’s interests and short positions in any ‘relevant securities’ of ICG.

All ‘dealings’ in ‘relevant securities’ of ICG by Bidco, or by any party ‘acting in concert’ with Bidco, must also be disclosed by no later than 12 noon (Irish/UK time) on the ‘business’ day following the date of the relevant transaction. If two or more persons co-operate on the basis of an agreement, either express or tacit, either oral or written, to acquire for one or more of them an ‘interest’ in ‘relevant securities’, they will be deemed to be a single person for these purposes.

Disclosure tables, giving details of the companies in whose ‘relevant securities’ and ‘dealings’ should be disclosed, can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie.   

‘Interests’ in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an ‘interest’ by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks in this section are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel’s website. If you are in any doubt as to whether or not you are required to disclose a dealing under Rule 8, please consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.

Publication on Website

Pursuant to Rule 26.1 of the Irish Takeover Rules, a copy of this Announcement will be made available on ICG’s website (www.icg.ie) by no later than 12:00 noon (Irish/UK time) on the business day following the date of this Announcement. Neither the content of any such website, nor the content of any other website accessible from hyperlinks on such website, is incorporated into, or forms part of, this Announcement.

General

This Announcement has been prepared for the purpose of complying with the laws of Ireland and the Irish Takeover Rules, and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws of jurisdictions outside of Ireland.

The release, publication or distribution of this Announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Persons who are not resident in Ireland or the United Kingdom, or who are subject to the laws of another jurisdiction, should inform themselves about, and observe, any applicable legal or regulatory requirements. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, ICG disclaims any responsibility or liability for the violation of such restrictions by any person.

Any decision in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Document. If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your appropriately authorised independent financial adviser.